cyrilzakka/clinical-trials huggingface dataset:
Right Sided Colon Polyp Miss Rate: Impact Of Retroflexion In The Right Colon

Colonoscopy is the gold standard screening test for colorectal cancer. Removal of pre-malignant colon polyps during colonoscopy reduces colorectal cancer mortality by over 50%. However, while colonoscopy is highly effective at preventing distal (left sided) colon cancers, it provides only limited protection from cancer in the proximal (right side) colon. Our goal is to determine if additional pre-cancerous colon polyps can be identified by looking at the right side of the colon in retroflexion. During retroflexion the tip of the colonoscope is turned 180 degrees; allowing the doctor to view the backs of colonic folds. If additional polyps can be identified in this manner colonoscopy will become a more efficient method of screening for colon cancer.

In order to evaluate how effective right colon retroflexion is at detecting polyps in the proximal colon we plan on performing a randomized, controlled trial. Patients undergoing screening or follow up colonoscopy will be invited to participate in the study. Those patients who agree to participate will be randomized into one of two groups once the colonoscope is fully inserted. Group one will have the right side of their colon examined for polyps with the endoscope looking forward (traditional form of examination) followed by repeat examination of the right side of the colon with the colonosocpe in retroflexion (looking backwards). Polyps seen during each section of the exam will be removed and manner in which the polyps were found/ removed will be recorded. Following the two exams of the right side of the colon the colonoscopy will be completed in the usual manner. The duration of each portion of colonoscopy will be recorded. After the procedure is completed the physician performing the colonoscopy will rate difficulty of the procedure and confidence with quality of the examination. Pathology results for each polyp will be recorded once available. There will be no study related follow up after the pathology results are recorded.


Eligibility Criteria:
Inclusion Criteria:

* • Patients \>18 years of age undergoing colonoscopy for colorectal cancer screening or routine polyp surveillance

Exclusion Criteria:

* • Failure to intubate the cecum during colonoscope insertion

  * Prior right colon resection
  * Known polyposis syndrome or polyposis identified at colonoscopy
  * Inflammatory bowel disease
  * Preparation of the colon is judged fair or poor using Boston Bowel Preparation Scale.
Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora

Human and animal studies demonstrate that xylooligosaccharides (XOS) are a highly efficacious prebiotic ingredient that delivers benefits at a minimum level of 1.4 g/day (d), which is much lower than levels required by fructooligosaccharides (FOS, 5 g/d) or galactooligosaccharides (GOS, 8 g/d). XOS promotes gastrointestinal regularity and relieves diarrhea and constipation at 0.7 g/d and 1.4 g/d, respectively. Xylooligosaccharides may also reduce blood cholesterol and may improve glycemic control, although more data from clinical trials are needed to confirm preliminary findings.


Eligibility Criteria:
Inclusion Criteria:

1. Age 20-50 years of age at screen.
2. In generally good health
3. Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.

Exclusion Criteria:

1. Any history of gastrointestinal disease except for appendectomy
2. No antibiotic, pre- or probiotic or laxative use during the 2 months before the study.
3. Any subject with a history of diabetes mellitus, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP\>160mmHg, diastolic BP\>95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.
4. Any subject with a screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.
5. Any subject who currently uses tobacco products.
6. Any subject who is pregnant or lactating, or becomes pregnant during the study.
7. Any subject who is unable or unwilling to comply with the study protocol.
Admission of the Patient to the Clinic After Surgery

Aim:This research was designed as a randomized controlled study to examine the effect of the game-based virtual reality learning method on the patient's post-operative admission to the clinic on the learning outcomes of the students.

Desing: This study was designed as a randomized controlled study to examine the effect of the game-based virtual reality learning method on the patient's post-operative admission to the clinic on the learning outcomes of the students.

Metod: The universe of the research will be nursing students who have taken the Surgical Diseases Nursing Course at Gazi University Faculty of Health Sciences Nursing Department in the 2021-2022 academic year. As a result of the power analysis using the G-power 3.1.9.7 package program; The effect size was calculated as 0.40 (It was seen from the literature studies that the effect size of the change in the knowledge score of the two groups was large effect size), and the total number of 68 samples is sufficient with 90% power, 5% margin of error, 95% confidence level, 20% drop-out Considering the rate of study, it was found sufficient to work with at least 82 people (Experiment: 41, Control: 41). For research data, "descriptive features form", "knowledge test form", "skill evaluation checklist", "student opinions form about game-based virtual reality game application", egameflow scale will be used.


Eligibility Criteria:
Inclusion Criteria:

* Students who voluntarily participated in the study
* Students who have taken all the subjects of the Surgical Diseases Nursing Course
* Students with smartphones, tablets, computers
* Students with internet access

Exclusion Criteria:

* Students who do not participate in the theoretical training
* Students who take the Surgical Diseases Nursing Course from below
* Students who do not want to continue the research
* Students who do not fill out the data collection forms at any stage
* Students who do not participate in the virtual reality-based game application
* Students who do not participate in any of the skills assessment
* Students who fill in the data collection forms incompletely
Wearable Technological Device Applied to Patients with Chronic Pain

Within the scope of this research, a single session of Wearable Technological Device (Exopulse Molli-Suit) will be applied to patients with chronic back and neck pain. The results will be evaluated acutely, after 24 hours, after 1 week and after 1 month.

After initial evaluations, patients received a single session for 1 hour. Exopulse Mollii Suit will be applied. The stimulation level of the electrodes will be determined by the automatically by the system in accordance with the level of pain they indicate for their parts, individually tailored to the person.

will be created. Patients will wear the Exopulse Mollii Suit, which is suitable for their body size, Hacettepe University Physics They will dress in the room allocated for them at the Faculty of Treatment and Rehabilitation. After each use The hygiene of Exopulse Mollii Suits has been evaluated at Hacettepe University Faculty of Physical Therapy and Rehabilitation in this will be provided with the help of a special device included in the scope. Initial assessments will be made immediately will be repeated three more times: after the intervention, 24 hours after the intervention and 4 weeks after the intervention.

All data will be collected face-to-face from patients using the instruments mentioned above.

Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 20-65
* Pain intensity should be at least 5 according to a numeric scale (low back pain and neck pain)
* no pain for at least 6 months (healthy people)

Exclusion Criteria:

* Malignant condition,
* People with systemic diseases such as neurological, psychological, cardiovascular, rheumatologic diseases and loss of function due to these diseases,
* History of previous surgery on the spine and upper extremities, including the cervical and lumbar region,
* Fractures in the spine and upper extremities, including the cervical and lumbar region, with a history of inflammation,
* Acute infection,
* Attending another rehabilitation program,
* Refused to participate in the study and did not give written informed consent
A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)

A total of 608 participants with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study; participants will receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin.


Eligibility Criteria:
Inclusion Criteria:

* Is able to read and sign a consent form;
* Is from ≥18 to \<90 years of age;
* Has diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device;
* Tests positive for Clostridium difficile;
* If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study.

Exclusion Criteria:

* Has toxic megacolon and/or known small bowel ileus;
* Has received treatment with intravenous immune globulin (IVIG) within the past 30 days;
* Has received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study;
* Has received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working;
* Has received an investigational vaccine against Clostridium difficile;
* Has received an investigational product containing monoclonal antibodies against toxin A or B within 180 days;
* Has more than 2 episodes of CDAD within 90 days;
* Has had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months (this does not include appendectomy or cholecystectomy);
* Has a history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis;
* Is unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study;
* Is unable to discontinue opiate treatment unless on a stable dose;
* Has known positive stool cultures for other enteropathogens including but not limited to Salmonella, Shigella, and Campylobacter;
* Has had stool studies positive for pathogenic ova and/or parasites;
* Has an intolerance or hypersensitivity to daptomycin and/or vancomycin;
* Has a life-threatening illness at the time of enrollment;
* Has poor concurrent medical risks that in the opinion of the Investigator the participant should not enroll;
* Has received an investigational drug or participated in any experimental procedure within 1 month;
* Has human immunodeficiency virus (HIV), a cluster of differentiation (CD) 4 count \<200 cells/mm\^3 within 6 months of start of study therapy;
* Anticipates that certain antibacterial therapy for a non-CDAD infection will be required for \>7 days;
* Is unable to discontinue Saccharomyces or similar probiotic;
* Is on a concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy;
* Is unable to comply with the protocol requirements;
* Has any condition that, in the opinion of the Investigator, might interfere;
* Is not expected to live for less than 8 weeks.
Sedation and Analgesia Using PFK Versus General Anesthesia in Urological Procedures

Anesthesia in urological surgeries might constitute a great challenge to anesthesiologists. Especially that a great proportion of these patients are elderly with a lot of comorbidities. This put these patients at the risk of developing medical adverse events after being anesthetized by general anesthesia. The aim of this study is to compare between intravenous sedation with analgesia versus general anesthesia in patients undergoing urological surgical procedures.

Anesthesia in urological surgeries might constitute a great challenge to anesthesiologists. Especially that a great proportion of these patients are elderly with a lot of comorbidities. This put these patients at the risk of developing medical adverse events after being anesthetized by general anesthesia. The aim of this study is to compare between intravenous sedation with analgesia versus general anesthesia in patients undergoing urological surgical procedures.

The first group which underwent general anesthesia, was anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Laryngeal mask airway was then inserted.

The second group underwent intravenous sedation and analgesia by using a mixture of Fentanyl, Propofol and Ketamine (PFK mixture). The mixture consists of 100 mcg Fentanyl, 100 mg Propofol, 100 mg of Ketamine. In addition, 40 mg of Lidocaine were added, this aimed to reduce the pain on injection caused by Propofol. Moreover, 4 ml of water of injection were added to the mixture. This resulted in a mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine. By this, each ml of the mixture contained 10 mg (ketamine and propofol) + 5 mcg fentanyl. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on support of 3 L/min O2.

Eligibility Criteria:
Inclusion Criteria:

* patients above the age of 30 years
* patients who were admitted for minor urological surgeries under the care of urology team. Minor urological procedures, included cystoscopy, trans-urethral resection of tumor (TURT), uretroscopy, double J insertion, and double J removal.

Exclusion Criteria:

* patient refusal.
* urgent and emergency cases, which were not elective procedures.
* Surgeries that were expected to take a long duration (more than 1.5 hour).
Initiative in LYon for Lung cAncer Screening Development - Prevalence Study

Screening at-risk subjects with low-dose computed tomography (CT) efficiently reduces lung cancer specific mortality. However screening efficiency relies on the at-risk population's criteria definition and its participation rate to the screening. In France, there are concerns regarding the participation rates to national cancer screening that are quite low (around 50% and 32% of the eligible population for breast cancer and colorectal cancer respectively). Before organizing national lung cancer screening it is then crucial to determine the factors impacting the at-risk subjects willingness to participate in lung cancer screening.

The Lyon University Hospital is the second biggest hospital in France with more than 23,000 employees distributed among more than 160 professions representing every level of education or working conditions. Its population is heterogeneous and wide enough to perform a prevalence study assessing the willingness to participate among the at-risk population.

ILYAD is a prospective study performed by anonymous questionnaires that will be submitted to the 23,000 employees of the Lyon University Hospital. The study main objective is to evaluate the at-risk population presence in the Lyon University Hospital population, as defined by NELSON criteria and selection criteria for lung cancer screening (PLCOm2012 scoring), and its willingness to participate to a lung-cancer screening with low-dose CT. This might help further efficient national lung cancer screening campaign organization.


Eligibility Criteria:
Inclusion Criteria:

* Aged ≥ 18 years old
* Employee from the Lyon University Hospital (receiving salary from the Lyon University Hospital)
* Person who has willingness to respond the survey

Exclusion Criteria:

* Employees not hired by the Lyon University Hospital
* Employees who have not willingness to participate in the survey
Evaluation of Myocardial Sympathetic Denervation in Parkinson's Disease Using [18F]FDOPA

The purpose of this study is to evaluate the added value of PET-CT with \[18F\]FDOPA tracer for Assessment of the Myocardial Sympathetic Denervation in patients with or suspected with Parkinson's disease.

The investigators expect to see normal values of uptake ratio of \[18F\]FDOPA , in patients with no synuclein underline pathology or previously known cardiovascular disease (no history of high blood pressure or take medications that influence the sympathetic system- exclusion criteria). Low values of uptake ratio is presumed to be found in patients diagnosed with Parkinson's disease or other synuclein pathology.

The expected normal ratio of Heart/liver uptake values will be determined from scans of patients refered to \[18F\]FDOPA scan and were found to have normal \[18F\]FDOPA scan of the basal ganglia and no cardiovascular diseases.

L-3,4-dihydroxy-6-\[18F\]fluoro-phenylalanine (\[18F\]FDOPA) might be a useful tracer for assessing myocardial sympathetic denervation in Parkinson's disease (PD) Patients. Compared to the routinely used I123 MIBG scan, \[18F\]FDOPA seems to have an advantage for the following reasons:

1. meta-iodobenzylguanidine (MIBG) is a false analog of norepinephrine while \[18F\]FDOPA is the radiolabelled form of DOPA, a direct precursor of dopamine which is subsequently converted to norepinephrine
2. 123I MIBG, un-like norepinephrine, dose not undergo intracellular metabolism (19) while \[18F\]FDOPA undergo complex intracellular metabolism (17)
3. Studies have shown that I123 MIBG reuptake is almost exclusive by uptake mechanism 1. Uptake-2 mechanism of 123I-MIBG by the myocardium is not significant. Reuptake of norepinephrine (NE) in the synaptic cleft and is mainly by uptake 1 system but also in small amount by uptake 2 systems. The investigators assumption is that this double mechanism of reuptake will increase the concentration of \[18F\]FDOPA for better imaging

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18
2. Signed Informed Consent
3. Patients referred for F-dopa scan of basal ganglia in the evaluation of Parkinson's disease or other extra pyramidal motor disorders.
4. Patients diagnosed with Parkinson's disease.

Exclusion Criteria:

1. Age \< 18
2. Previous diagnosed Heart Disease.
3. History of High blood pressure.
4. On medications that influence the sympathetic system.
Evaluating the Feasibility of Acapella® Choice as a Dysphonia Treatment

A feasibility study to identify the immediate effect on the voices of patients with voice disorders (muscle tension dysphonia, vocal fold palsy or presbylaryngis) produced by exercising with Acapella Choice as a form of semioccluded vocal tract exercise (SOVTE).

This feasibility study is the natural extension of the researchers' recently completed study (R\&D 16/0242) which assessed how the use of an Acapella Choice (Smiths Medical) positive expiratory pressure (PEP) device as a semi-occluded vocal tract exercise (SOVTE) impacted acoustic, electroglottographic and aerodynamic measures of the voice in a group of normophonic volunteers. In that study, Acapella Choice was found to offer significantly greater oscillating intraoral pressures than techniques in current clinical practice and was found to have measurable benefits in terms of producing a louder and more economical voice. It offered the largest oscillating pressures, likened to a 'massage' of the vocal organs, giving it great therapeutic promise for patients with excess vocal tract tension.

This study seeks to evaluate the immediate effects of Acapella Choice as a voice exercise in patients with Muscle Tension Dysphonia, Presbylaryngis and Vocal Fold Palsy, and compare this to the widely-used voice rehabilitation technique of phonation into a tube held under water (henceforward referred to as "Tube"). Patients will be recruited from four weekly Voice Clinics held at the Royal National Throat Nose and Ear Hospital where their diagnosis will be confirmed. They will be invited to attend a single experimental session during which time they will exercise both with Acapella Choice and with Tube. Baseline and outcome voice measures will be taken and a short questionnaire will be completed, eliciting perceptions of the two exercises and any changes which were felt to have resulted from them.

The researchers' previous work suggests that Acapella Choice as a SOVTE may offer significant clinical benefits in terms of improved efficacy of therapy. It is suggested that it also offers patients a more convenient and user-friendly form of exercise which may well improve compliance and result in better outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Able to understand written English without the need for an interpreter,
* No diagnosed communication impairment
* Endoscopically confirmed primary ENT diagnosis of either:

  1. muscle tension dysphonia (with no laryngeal abnormality),
  2. Vocal fold palsy
  3. Presbylaryngis.

Exclusion Criteria:

* Previous SLT input
* Any of the following possible contraindications for PEP therapy:

  * Inability to tolerate increased work of breathing,
  * ICP (intracranial pressure) \> 20mm Hg,
  * Recent facial/oral/skull surgery or trauma,
  * Oesophageal surgery,
  * Untreated pneumothorax,
  * Known or suspected tympanic membrane rupture/other middle ear pathology,
  * Haemodynamic instability,
  * Acute sinusitis,
  * Epistaxis,
  * Active haemoptysis,
  * Nausea